New Enzyme Products Launched at the AACR 2017 with Higher Specific Collagenase and Caseinase Activities

Worthington Biochemical Corporation announced the release of the new 2017 – 2018 Enzyme and Biochemical Catalog for biochemistry, cell biology, molecular biology and bioprocessing applications at the American Association of Cancer Research (AACR) 2017 in Washington, D.C.

As an enzyme specialty company with a solid 70-year history, the Worthington name has become synonymous with the term “primary producer”. New products highlighted in the guide include

Celase^® GMP enzyme to support pre-clinical research and collagenase type 6 and type 7 for primary cell isolation applications requiring strong digestive capabilities.

“We are proud to release our new catalog focusing on cell and molecular biology, tissue dissociation and protein research,” said Jim Zacka, vice president at Worthington. “Announcing its availability at the AACR conference this week, shows the company’s continuing commitment to keep pace with industry trends as more and more studies move from medical research to the clinic”.